ReviewInflammatory bowel diseases2014
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.
Review in Inflammatory bowel diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Prevalence of inflammatory bowel disease across states: estimates based on claims database.Inflammatory bowel diseases · 2026Article
- Article
- Inflammatory Bowel Disease Prevalence: Surveillance data from the U.S. National Health and Nutrition Examination Survey.Preventive medicine reports · 2023Article
- Increasing Incidence of Pouchitis Between 1996 and 2018: A Population-Based Danish Cohort Study.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Article
- Inflammatory bowel disease type influences development of elevated liver enzymes.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
- The Cumulative Incidence of Pouchitis in Pediatric Patients With Ulcerative Colitis.Inflammatory bowel diseases · 2022Article
- Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021Article
- Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.Inflammatory bowel diseases · 2018Review
- Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.Clinical pharmacokinetics · 2018Review
- Health-Risk Behaviors and Chronic Conditions Among Adults with Inflammatory Bowel Disease - United States, 2015 and 2016.MMWR. Morbidity and mortality weekly report · 2018Article
- PIAS3-mediated feedback loops promote chronic colitis-associated malignant transformation.Theranostics · 2018Article
- Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database.Inflammatory bowel diseases · 2017Article
- Hospitalizations for Crohn's Disease - United States, 2003-2013.MMWR. Morbidity and mortality weekly report · 2017Article
- Peroxisome Proliferator-activated Receptor-γ Coactivator 1-α (PGC1α) Protects against Experimental Murine Colitis.The Journal of biological chemistry · 2016Article
- Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.Therapeutic advances in chronic disease · 2015Review
- Transition readiness in pediatric patients with inflammatory bowel disease: patient survey of self-management skills.Journal of pediatric gastroenterology and nutrition · 2015Article
- NOD-like receptors in intestinal homeostasis and epithelial tissue repair.International journal of molecular sciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
This review describes the history of U.S. government funding for surveillance programs in inflammatory bowel diseases (IBD), provides current estimates of the incidence and prevalence of IBD in the United States, and enumerates a number of challenges faced by current and future IBD surveillance programs. A rationale for expanding the focus of IBD surveillance beyond counts of incidence and prevalence, to provide a greater understanding of the burden of IBD, disease etiology, and pathogenesis, is provided. Lessons learned from other countries are summarized, in addition to potential resources that may be used to optimize a new form of IBD surveillance in the United States. A consensus recommendation on the goals and available resources for a new model for disease surveillance are provided. This new model should focus on "surveillance of the burden of disease," including (1) natural history of disease and (2) outcomes and complications of the disease and/or treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.